SynCo Bio Partners
SynCo Bio Partners is an Amsterdam-based biopharmaceutical contract manufacturing organization providing GMP development and manufacturing services for microbial- and mammalian-derived biologics.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
SynCo Bio Partners B.V. is a biopharmaceutical good manufacturing practice contract manufacturing organization headquartered in Amsterdam, the Netherlands. It supports biotechnology and pharmaceutical companies with integrated development, production, filling, and regulatory supply services for biologic drug substances and drug products. Its work spans early process development, preclinical and clinical material, regulatory approval, commercial manufacturing, and ongoing market supply. The company operates multipurpose GMP facilities capable of handling both microbial and mammalian production platforms. This combination allows SynCo to work on a range of biological products, including recombinant proteins, vaccines, and live biotherapeutic products. Its service model is designed to support projects from small biotechnology companies as well as larger pharmaceutical organizations, with manufacturing intended for European, North American, Asian, and broader international markets. SynCo's operating history traces back to the Amsterdam facility established as the European headquarters of Cetus Corporation's EuroCetus B.V. in 1988. The facility subsequently became part of Chiron Corporation after Chiron acquired Cetus in 1992. During the 1990s and early 2000s, it obtained licenses and approvals connected with production of interleukin-2, pertussis vaccine materials, meningococcal polysaccharides, and CRM197 carrier protein used in conjugate-vaccine production. The site was acquired by Dr. William J. Rutter in 2000, when SynCo Bio Partners B.V. was established. Over the following years, SynCo expanded its manufacturing infrastructure, aseptic filling capability, process-development scope, and regulatory reach. Facility upgrades included new air-handling systems, a larger aseptic filling machine, expanded GMP areas, and an enlarged Class A zone intended to support larger batches and new product launches. Regulatory authorizations were reported from European, Canadian, Korean, Brazilian, and United States authorities for different commercial manufacturing activities. In 2018, SynCo Bio Partners was acquired by Wacker Chemie AG and integrated into Wacker Biotech GmbH. It therefore operates as part of the Wacker Biotech organization rather than as an independently listed company. The business is positioned around specialized, regulated biologics manufacturing, particularly for organizations that need an external partner capable of moving a product from development through commercial supply.
History
SynCo Bio Partners developed from a long-running biopharmaceutical manufacturing site in Amsterdam. In 1988, Cetus Corporation established EuroCetus B.V. as its European headquarters. The site soon became involved in regulated production activities: between 1990 and 1991, it was licensed to produce and release ProLeukin, an interleukin-2 product, for Europe and most other global markets apart from the United States and Japan. In 1992, Chiron Corporation acquired Cetus, and EuroCetus became Chiron B.V. The Amsterdam operation continued to broaden its vaccine-related manufacturing activities. In 1996, it received authorization associated with commercial pertussis-vaccine production. In 1997, the World Health Organization licensed the facility for commercial production of meningitis A polysaccharides. Between 1997 and 1999, the site also received approvals from the United Kingdom and Italian authorities for meningitis C polysaccharide and CRM197 carrier-protein production used in the conjugate vaccine Menjugate. The facility changed ownership in 2000, when Dr. William J. Rutter acquired it and established SynCo Bio Partners B.V. The new company retained the site's emphasis on regulated biologics manufacturing while developing a broader contract-services model. In 2001, the facility obtained authorization from the European Medicines Agency and Health Canada for manufacturing meningitis C polysaccharides and CRM197 carrier protein for Menjugate production. Infrastructure investment continued during the mid-2000s. New air-handling systems were completed across the facilities in 2004. In 2005, SynCo installed a new aseptic filling machine in its Class A zone, increasing potential batch sizes and broadening its filling range. The company also expanded its GMP facilities to support a wider selection of protein, vaccine, and live-biotherapeutic projects. In 2006, the site received authorization from the Korean regulatory authority for commercial production. SynCo enlarged its process-development capabilities in 2008, enabling the organization to undertake a wider range of development projects. In 2009, it received authorization from Brazil's Anvisa for commercial production. A further expansion of the aseptic filling Class A zone was completed in 2011, improving the site's ability to support product launches in the United States and other international markets. The facility's regulatory history continued with United States Food and Drug Administration authorization for commercial production of VaxChora in 2016. This reflected SynCo's role in manufacturing products intended for global commercial distribution and reinforced its position among contract manufacturers with both clinical and commercial biologics experience. In 2018, Wacker Chemie AG acquired SynCo Bio Partners B.V. and made it part of Wacker Biotech GmbH. The transaction placed SynCo within a larger biopharmaceutical services group while preserving its identity as an Amsterdam-based manufacturing operation. Its core proposition remains integrated GMP support for microbial- and mammalian-based biologics, covering process development, clinical supply, commercial production, aseptic filling, and worldwide market supply.
- 2018
Acquisition by Wacker Chemie
[1]SynCo Bio Partners is acquired by Wacker Chemie AG and becomes part of Wacker Biotech GmbH.
- 2016
FDA authorization for VaxChora production
[1]The facility receives United States FDA authorization for commercial manufacturing of VaxChora.
- 2011
Class A filling area expanded
[1]Expansion of the aseptic filling Class A zone improves support for new product launches in the United States and worldwide.
- 2008
Process-development capabilities broadened
[1]The company expands process-development capacity to handle a wider range of customer projects.
- 2005
Aseptic filling and GMP capacity expanded
[1]SynCo installs a larger aseptic filling machine and expands GMP facilities for protein, vaccine, and live-biotherapeutic products.
- 2004
Air-handling systems upgraded
[1]New air-handling systems are completed throughout the manufacturing facilities.
- 2000
SynCo Bio Partners is established
[1]Dr. William J. Rutter acquires the facility and establishes SynCo Bio Partners B.V.
- 1997
WHO authorization for meningitis A polysaccharides
[1]The World Health Organization licenses the facility for commercial production of meningitis A polysaccharides.
- 1996
Pertussis-vaccine manufacturing authorization
[1]The facility receives a license associated with commercial pertussis-vaccine production.
- 1992
The site becomes part of Chiron
[1]Following Chiron Corporation's acquisition of Cetus, EuroCetus B.V. becomes Chiron B.V.
Products and positioning
A specialized, fully integrated GMP contract manufacturing partner for biologics, combining microbial and mammalian production capabilities with clinical and commercial manufacturing experience.
Interleukin-2 biologic
ProLeukin
The Amsterdam predecessor facility was licensed in the early 1990s for production and release of ProLeukin, an interleukin-2 product, for European and selected international markets. This authorization illustrates the site's early role in regulated commercial biologics manufacturing.
Conjugate-vaccine components
Menjugate-related materials
SynCo's predecessor facility manufactured meningitis C polysaccharide and CRM197 carrier protein used in production of the conjugate vaccine Menjugate. Regulatory authorizations for these materials were obtained from European and Canadian authorities in the late 1990s and early 2000s.
Vaccine · 2016
VaxChora
VaxChora is a cholera vaccine associated with the facility's United States commercial manufacturing authorization in 2016. The authorization demonstrates SynCo's capacity to manufacture a commercially supplied vaccine under GMP conditions.
Contract-manufactured biologics
Microbial and mammalian biopharmaceuticals
SynCo provides manufacturing for biologic drug substances and products made using microbial or mammalian systems. Services can extend from process development and clinical material through commercial GMP production and market supply, depending on project requirements.
Brand decisions
2018
Join Wacker Biotech through acquisitionM&ABackground
SynCo had developed an Amsterdam-based GMP manufacturing operation serving clinical and commercial biologics projects, while Wacker Chemie operated a broader biopharmaceutical business through Wacker Biotech GmbH.
Action taken
Wacker Chemie AG acquired SynCo Bio Partners B.V. and incorporated it into Wacker Biotech GmbH.
Aftermath
SynCo became part of the Wacker Biotech organization and continued to represent an Amsterdam manufacturing site within the parent group's biopharmaceutical contract manufacturing activities.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/synco-bio-partners · Editorial policy · How profiles are compiled